Compare FSBW & CATX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FSBW | CATX |
|---|---|---|
| Founded | 1936 | 1983 |
| Country | United States | United States |
| Employees | 537 | N/A |
| Industry | Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 326.3M | 341.0M |
| IPO Year | 2011 | 2018 |
| Metric | FSBW | CATX |
|---|---|---|
| Price | $43.99 | $3.13 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 9 |
| Target Price | ★ $46.00 | $12.11 |
| AVG Volume (30 Days) | 18.1K | ★ 1.1M |
| Earning Date | 04-21-2026 | 05-11-2026 |
| Dividend Yield | ★ 2.79% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 2.07 | N/A |
| Revenue | ★ $4,612,000.00 | N/A |
| Revenue This Year | $14.94 | N/A |
| Revenue Next Year | $10.47 | N/A |
| P/E Ratio | $21.15 | ★ N/A |
| Revenue Growth | ★ 44.80 | N/A |
| 52 Week Low | $36.85 | $1.96 |
| 52 Week High | $45.85 | $6.16 |
| Indicator | FSBW | CATX |
|---|---|---|
| Relative Strength Index (RSI) | 53.07 | 52.16 |
| Support Level | $40.96 | $2.82 |
| Resistance Level | $43.70 | $4.27 |
| Average True Range (ATR) | 0.95 | 0.17 |
| MACD | -0.01 | 0.04 |
| Stochastic Oscillator | 70.87 | 72.03 |
FS Bancorp Inc is the holding company of First Security Bank, a diversified lender with a focus on the origination of commercial real estate, one-to-four-family, and home equity loans, consumer loans, including a variety of indirect home improvement (fixture secured loans), and marine loans, and commercial business loans. The company has two operating segments; The commercial and consumer banking segment provides diversified financial products and services to its commercial and consumer customers through Bank branches, automated teller machines, online banking platforms, mobile banking apps, and telephone banking; and The home lending segment originates one-to-four-family residential mortgage loans for sale in the secondary markets as well as loans held for investment.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.